Nicotine replacement therapy as a smoking cessation aid among disadvantaged smokers: What answers do we need?

Christine Paul; Luke Wolfenden; Flora Tzelepis; Serene Yoong; Jenny Bowman; Paula Wye; Emma Sherwood; Shiho Rose; John Wiggers

doi:10.1111/dar.12362

Nicotine replacement therapy as a smoking cessation aid among disadvantaged smokers: What answers do we need?

Drug Alcohol Rev. 2016 Nov;35(6):785-789. doi: 10.1111/dar.12362. Epub 2015 Dec 14.

Authors

Christine Paul^{1

2}, Luke Wolfenden^{1

2

3}, Flora Tzelepis^{1

2

3}, Serene Yoong^{1

2

3}, Jenny Bowman^{1

2}, Paula Wye^{2

3}, Emma Sherwood^{1

2}, Shiho Rose^{1

2}, John Wiggers^{1

2

3}

Affiliations

¹ Priority Research Centre for Health Behaviour, University of Newcastle, Newcastle, Australia.
² Hunter Medical Research Institute, HMRI Building, University of Newcastle, Newcastle, Australia.
³ Hunter New England Population Health, Newcastle, Australia.

PMID: 26661119
DOI: 10.1111/dar.12362

Abstract

In Australia and New Zealand, population groups who experience social disadvantage smoke at much higher rates than the general population. As there are limited data specific to these groups regarding the success of nicotine replacement therapy for smoking cessation, this commentary will provide an overview of the relevant international literature supplemented with observational data relevant to the policy contexts in Australia and New Zealand. [Paul C, Wolfenden L, Tzelepis F, Yoong S, Bowman J, Wye P, Sherwood E, Rose S, Wiggers J. Nicotine replacement therapy as a smoking cessation aid among disadvantaged smokers: What answers do we need? Drug Alcohol Rev 2016;35:785-789].

Keywords: Australia; New Zealand; nicotinic agonist; population group; smoking cessation.

MeSH terms

Humans
Nicotine / therapeutic use*
Smoking Cessation / methods*
Smoking Prevention / methods*
Tobacco Use Cessation Devices*
Tobacco Use Disorder / drug therapy*

Substances

Nicotine